Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
CA 2445322 C · Owner: Hirakata, Masao · Inventors: Fuse, Hiromitsu; Sugiyama, Yasuo; Hirakata, Masao
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The ABCA1 mRNA expression-promoting agent LXR.alpha. mRNA , expression-promoting agent ABCG1 mRNA expression-promoting , agent cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity. The ABC expression promoting agent pioglitazone, or a salt thereof, is used for the treatment of arteriosclerosis obliterans.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 24, 2002 and granted June 14, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 24, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 24, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.